Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase

Katherine A. Hurley, Thiago M.A. Santos, Molly R. Fensterwald, Madhusudan Rajendran, Jared T. Moore, Edward I. Balmond, Brice J. Blahnik, Katherine C. Faulkner, Marie H. Foss, Victoria A. Heinrich, Matthew G. Lammers, Lucas C. Moore, Gregory D. Reynolds, Galen P. Shearn-Nance, Brian A. Stearns, Zi W. Yao, Jared T. Shaw, Douglas B. Weibel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bacterial DNA gyrase is an essential type II topoisomerase that enables cells to overcome topological barriers encountered during replication, transcription, recombination, and repair. This enzyme is ubiquitous in bacteria and represents an important clinical target for antibacterial therapy. In this paper we report the characterization of three exciting new gyramide analogs - from a library of 183 derivatives - that are potent inhibitors of DNA gyrase and are active against clinical strains of Gram-negative bacteria (Escherichia coli, Shigella flexneri, and Salmonella enterica; 3 of 10 wild-type strains tested) and Gram-positive bacteria (Bacillus spp., Enterococcus spp., Staphylococcus spp., and Streptococcus spp.; all 9 of the wild-type strains tested). E. coli strains resistant to the DNA gyrase inhibitors ciprofloxacin and novobiocin display very little cross-resistance to these new gyramides. In vitro studies demonstrate that the new analogs are potent inhibitors of the DNA supercoiling activity of DNA gyrase (IC50s of 47-170 nM) but do not alter the enzyme's ATPase activity. Although mutations that confer bacterial cells resistant to these new gyramides map to the genes encoding the subunits of the DNA gyrase (gyrA and gyrB genes), overexpression of GyrA, GyrB, or GyrA and GyrB together does not suppress the inhibitory effect of the gyramides. These observations support the hypothesis that the gyramides inhibit DNA gyrase using a mechanism that is unique from other known inhibitors.

Original languageEnglish (US)
Pages (from-to)942-951
Number of pages10
JournalMedChemComm
Volume8
Issue number5
DOIs
StatePublished - 2017

Fingerprint

Aminocoumarins
DNA Gyrase
Quinolones
Bacteria
Topoisomerase II Inhibitors
Escherichia coli
Novobiocin
Shigella flexneri
Recombinational DNA Repair
Bacterial DNA
Type II DNA Topoisomerase
Salmonella
Gene encoding
Salmonella enterica
Enterococcus
Gram-Positive Bacteria
Bacilli
Enzymes
Transcription
Ciprofloxacin

ASJC Scopus subject areas

  • Biochemistry
  • Pharmaceutical Science

Cite this

Hurley, K. A., Santos, T. M. A., Fensterwald, M. R., Rajendran, M., Moore, J. T., Balmond, E. I., ... Weibel, D. B. (2017). Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase. MedChemComm, 8(5), 942-951. https://doi.org/10.1039/c7md00012j

Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase. / Hurley, Katherine A.; Santos, Thiago M.A.; Fensterwald, Molly R.; Rajendran, Madhusudan; Moore, Jared T.; Balmond, Edward I.; Blahnik, Brice J.; Faulkner, Katherine C.; Foss, Marie H.; Heinrich, Victoria A.; Lammers, Matthew G.; Moore, Lucas C.; Reynolds, Gregory D.; Shearn-Nance, Galen P.; Stearns, Brian A.; Yao, Zi W.; Shaw, Jared T.; Weibel, Douglas B.

In: MedChemComm, Vol. 8, No. 5, 2017, p. 942-951.

Research output: Contribution to journalArticle

Hurley, KA, Santos, TMA, Fensterwald, MR, Rajendran, M, Moore, JT, Balmond, EI, Blahnik, BJ, Faulkner, KC, Foss, MH, Heinrich, VA, Lammers, MG, Moore, LC, Reynolds, GD, Shearn-Nance, GP, Stearns, BA, Yao, ZW, Shaw, JT & Weibel, DB 2017, 'Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase', MedChemComm, vol. 8, no. 5, pp. 942-951. https://doi.org/10.1039/c7md00012j
Hurley KA, Santos TMA, Fensterwald MR, Rajendran M, Moore JT, Balmond EI et al. Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase. MedChemComm. 2017;8(5):942-951. https://doi.org/10.1039/c7md00012j
Hurley, Katherine A. ; Santos, Thiago M.A. ; Fensterwald, Molly R. ; Rajendran, Madhusudan ; Moore, Jared T. ; Balmond, Edward I. ; Blahnik, Brice J. ; Faulkner, Katherine C. ; Foss, Marie H. ; Heinrich, Victoria A. ; Lammers, Matthew G. ; Moore, Lucas C. ; Reynolds, Gregory D. ; Shearn-Nance, Galen P. ; Stearns, Brian A. ; Yao, Zi W. ; Shaw, Jared T. ; Weibel, Douglas B. / Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase. In: MedChemComm. 2017 ; Vol. 8, No. 5. pp. 942-951.
@article{eb70f2e3501f4dfba1b83e7013a8635b,
title = "Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase",
abstract = "Bacterial DNA gyrase is an essential type II topoisomerase that enables cells to overcome topological barriers encountered during replication, transcription, recombination, and repair. This enzyme is ubiquitous in bacteria and represents an important clinical target for antibacterial therapy. In this paper we report the characterization of three exciting new gyramide analogs - from a library of 183 derivatives - that are potent inhibitors of DNA gyrase and are active against clinical strains of Gram-negative bacteria (Escherichia coli, Shigella flexneri, and Salmonella enterica; 3 of 10 wild-type strains tested) and Gram-positive bacteria (Bacillus spp., Enterococcus spp., Staphylococcus spp., and Streptococcus spp.; all 9 of the wild-type strains tested). E. coli strains resistant to the DNA gyrase inhibitors ciprofloxacin and novobiocin display very little cross-resistance to these new gyramides. In vitro studies demonstrate that the new analogs are potent inhibitors of the DNA supercoiling activity of DNA gyrase (IC50s of 47-170 nM) but do not alter the enzyme's ATPase activity. Although mutations that confer bacterial cells resistant to these new gyramides map to the genes encoding the subunits of the DNA gyrase (gyrA and gyrB genes), overexpression of GyrA, GyrB, or GyrA and GyrB together does not suppress the inhibitory effect of the gyramides. These observations support the hypothesis that the gyramides inhibit DNA gyrase using a mechanism that is unique from other known inhibitors.",
author = "Hurley, {Katherine A.} and Santos, {Thiago M.A.} and Fensterwald, {Molly R.} and Madhusudan Rajendran and Moore, {Jared T.} and Balmond, {Edward I.} and Blahnik, {Brice J.} and Faulkner, {Katherine C.} and Foss, {Marie H.} and Heinrich, {Victoria A.} and Lammers, {Matthew G.} and Moore, {Lucas C.} and Reynolds, {Gregory D.} and Shearn-Nance, {Galen P.} and Stearns, {Brian A.} and Yao, {Zi W.} and Shaw, {Jared T.} and Weibel, {Douglas B.}",
year = "2017",
doi = "10.1039/c7md00012j",
language = "English (US)",
volume = "8",
pages = "942--951",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "Royal Society of Chemistry",
number = "5",

}

TY - JOUR

T1 - Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase

AU - Hurley, Katherine A.

AU - Santos, Thiago M.A.

AU - Fensterwald, Molly R.

AU - Rajendran, Madhusudan

AU - Moore, Jared T.

AU - Balmond, Edward I.

AU - Blahnik, Brice J.

AU - Faulkner, Katherine C.

AU - Foss, Marie H.

AU - Heinrich, Victoria A.

AU - Lammers, Matthew G.

AU - Moore, Lucas C.

AU - Reynolds, Gregory D.

AU - Shearn-Nance, Galen P.

AU - Stearns, Brian A.

AU - Yao, Zi W.

AU - Shaw, Jared T.

AU - Weibel, Douglas B.

PY - 2017

Y1 - 2017

N2 - Bacterial DNA gyrase is an essential type II topoisomerase that enables cells to overcome topological barriers encountered during replication, transcription, recombination, and repair. This enzyme is ubiquitous in bacteria and represents an important clinical target for antibacterial therapy. In this paper we report the characterization of three exciting new gyramide analogs - from a library of 183 derivatives - that are potent inhibitors of DNA gyrase and are active against clinical strains of Gram-negative bacteria (Escherichia coli, Shigella flexneri, and Salmonella enterica; 3 of 10 wild-type strains tested) and Gram-positive bacteria (Bacillus spp., Enterococcus spp., Staphylococcus spp., and Streptococcus spp.; all 9 of the wild-type strains tested). E. coli strains resistant to the DNA gyrase inhibitors ciprofloxacin and novobiocin display very little cross-resistance to these new gyramides. In vitro studies demonstrate that the new analogs are potent inhibitors of the DNA supercoiling activity of DNA gyrase (IC50s of 47-170 nM) but do not alter the enzyme's ATPase activity. Although mutations that confer bacterial cells resistant to these new gyramides map to the genes encoding the subunits of the DNA gyrase (gyrA and gyrB genes), overexpression of GyrA, GyrB, or GyrA and GyrB together does not suppress the inhibitory effect of the gyramides. These observations support the hypothesis that the gyramides inhibit DNA gyrase using a mechanism that is unique from other known inhibitors.

AB - Bacterial DNA gyrase is an essential type II topoisomerase that enables cells to overcome topological barriers encountered during replication, transcription, recombination, and repair. This enzyme is ubiquitous in bacteria and represents an important clinical target for antibacterial therapy. In this paper we report the characterization of three exciting new gyramide analogs - from a library of 183 derivatives - that are potent inhibitors of DNA gyrase and are active against clinical strains of Gram-negative bacteria (Escherichia coli, Shigella flexneri, and Salmonella enterica; 3 of 10 wild-type strains tested) and Gram-positive bacteria (Bacillus spp., Enterococcus spp., Staphylococcus spp., and Streptococcus spp.; all 9 of the wild-type strains tested). E. coli strains resistant to the DNA gyrase inhibitors ciprofloxacin and novobiocin display very little cross-resistance to these new gyramides. In vitro studies demonstrate that the new analogs are potent inhibitors of the DNA supercoiling activity of DNA gyrase (IC50s of 47-170 nM) but do not alter the enzyme's ATPase activity. Although mutations that confer bacterial cells resistant to these new gyramides map to the genes encoding the subunits of the DNA gyrase (gyrA and gyrB genes), overexpression of GyrA, GyrB, or GyrA and GyrB together does not suppress the inhibitory effect of the gyramides. These observations support the hypothesis that the gyramides inhibit DNA gyrase using a mechanism that is unique from other known inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85021941222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021941222&partnerID=8YFLogxK

U2 - 10.1039/c7md00012j

DO - 10.1039/c7md00012j

M3 - Article

AN - SCOPUS:85021941222

VL - 8

SP - 942

EP - 951

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 5

ER -